153 related articles for article (PubMed ID: 35004240)
1. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
3. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
4. NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma.
Li D; Yang D; Cui S; Pan E; Yang P; Dai Z
Onco Targets Ther; 2021; 14():4261-4265. PubMed ID: 34321891
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
[TBL] [Abstract][Full Text] [Related]
6. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
Front Oncol; 2021; 11():621992. PubMed ID: 33718183
[TBL] [Abstract][Full Text] [Related]
7. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
[TBL] [Abstract][Full Text] [Related]
8. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
Li Y; Zhang FS; Guo L; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
[No Abstract] [Full Text] [Related]
9. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
11. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in
Liao BC; Hsu WH; Lee JH; Yang CY; Tsai TH; Liao WY; Ho CC; Lin CC; Shih JY; Yu CJ; Soo RA; Yang JC
JTO Clin Res Rep; 2021 Jan; 2(1):100099. PubMed ID: 34589970
[TBL] [Abstract][Full Text] [Related]
12.
Klempner SJ; Mehta P; Schrock AB; Ali SM; Ou SI
Lung Cancer (Auckl); 2017; 8():241-247. PubMed ID: 29255376
[TBL] [Abstract][Full Text] [Related]
13.
Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
[TBL] [Abstract][Full Text] [Related]
14. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Kato R; Hayashi H; Sakai K; Suzuki S; Haratani K; Takahama T; Tanizaki J; Nonagase Y; Tanaka K; Yoshida T; Takeda M; Yonesaka K; Kaneda H; Nishio K; Nakagawa K
Int J Clin Oncol; 2021 Sep; 26(9):1628-1639. PubMed ID: 34117553
[TBL] [Abstract][Full Text] [Related]
15. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
[TBL] [Abstract][Full Text] [Related]
16. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
17. Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib.
Wang Y; He Y; Tian P; Wang W; Wang K; Chuai S; Li Y; Zhao S; Wang Y; Li W
Transl Lung Cancer Res; 2020 Oct; 9(5):1952-1962. PubMed ID: 33209615
[TBL] [Abstract][Full Text] [Related]
18. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Kim C; Xi L; Cultraro CM; Wei F; Jones G; Cheng J; Shafiei A; Pham TH; Roper N; Akoth E; Ghafoor A; Misra V; Monkash N; Strom C; Tu M; Liao W; Chia D; Morris C; Steinberg SM; Bagheri H; Wong DTW; Raffeld M; Guha U
Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34283064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
